Adam Schatz, MD
Urology · Meridian, IDNPI 1316331705
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.5% of the total across 112 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 14.6% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for urology clinicians in ID, where the typical reported total is $3,075.
Across 112 payments — averaging $23.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$391
- Coloplast$293
- Bayer$198
- Sumitomo Pharma America, Inc.$197
- Accord Healthcare, Inc.$160
- Dendreon Pharmaceuticals LLC$159
- plus $1K from 26 others
Across 72 payments — averaging $4610.99 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ortho-clinical Diagnostics, Inc.$332K
What the payments were for
- Travel & lodging$2529%
- Food & beverage$2,42590%
- Education$40%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 16 | $391 |
| Coloplast | 3 | $293 |
| Bayer | 7 | $198 |
| Sumitomo Pharma America, Inc. | 7 | $197 |
| Accord Healthcare, Inc. | 9 | $160 |
| Dendreon Pharmaceuticals LLC | 8 | $159 |
| Teleflex LLC | 3 | $155 |
| Astellas Pharma US Inc | 5 | $129 |
| Pfizer | 8 | $122 |
| Merck | 6 | $120 |
| Urogen Pharma, Inc. | 6 | $98 |
| Johnson & Johnson | 4 | $87 |
| Endo USA, Inc. | 4 | $76 |
| Myovant Sciences Inc. | 4 | $68 |
| AstraZeneca | 3 | $45 |
| SN Holdings, LLC | 1 | $40 |
| Bluewind Medical | 1 | $39 |
| Boston Scientific | 2 | $36 |
| Tolmar Pharmaceuticals, Inc. | 2 | $31 |
| Novartis | 1 | $30 |
| Novo Nordisk | 1 | $24 |
| Amgen | 1 | $24 |
| Alnylam Pharmaceuticals Inc. | 1 | $20 |
| Immunitybio, Inc. | 1 | $20 |
| Sanofi | 1 | $19 |
| Bioprotect Medical, Inc. | 1 | $19 |
| Rochester Medical Corporation | 1 | $18 |
| Sun Pharmaceutical Industries Inc. | 1 | $16 |
| Ferring Pharmaceuticals Inc. | 1 | $15 |
| Endo Pharmaceuticals Inc. | 1 | $14 |
| Pacira Pharmaceuticals Incorporated | 1 | $13 |
| Travere Therapeutics, Inc. | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,680 in reported general payments places this provider in the 35th percentile of 55 urology providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 175 | $114,522 |
| GemtesaVibegron | 111 | $68,604 |
| Testosterone | 41 | $11,606 |
| Tamsulosin Hcl | 575 | $6,481 |
| Tolterodine Tartrate ErTolterodine Tartrate | 34 | $5,290 |
| Estradiol | 68 | $4,157 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 36 | $3,382 |
| Testosterone Cypionate | 44 | $2,558 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 147 | $2,383 |
| Finasteride | 165 | $1,759 |
| Solifenacin Succinate | 18 | $1,755 |
| Potassium Citrate ErPotassium Citrate | 11 | $1,349 |
| Oxybutynin Chloride ErOxybutynin Chloride | 56 | $872 |
| Methenamine Hippurate | 38 | $763 |
| Dutasteride | 36 | $724 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $129 | $114,522175 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $197 | $68,604111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 55 urology providers in Idaho.
Other urology in Meridian
- Wade MunceyMeridian$9K
- John GreerMeridian$8K
- Dawn KingMeridian$8K
- Helen KuoMeridian$5K
- Brian AugeMeridian$5K
- Michael JacobsonMeridian$4K
- Kara SaperstonMeridian$4K
- Joseph WilliamsMeridian$4K
- Lisa ParrilloMeridian$3K
- Michael TaylorMeridian$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.